GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2010

PolyTherics and Zealand Ink PEGylated Peptide Therapeutics Collaboration

  • PolyTherics and Zealand Pharma entered a research collaboration focused on the development of PEGylated forms of peptide-based therapeutics against metabolic, cardiovascular, and gastrointestinal diseases.

    The partnership will apply PolyTherics’ PEGylation technologies to specific peptide candidates discovered by Zealand. Funding will come from the EUREKA Eurostars Program, which provides support to SMEs.

    The companies say their collaboration is expected to run for 24 months. During the first year they will carry out experimental research, and over the second 12 months they aim to select lead candidates for preclinical development.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?